EXACT Therapeutics AS (“EXACT-Tx”) is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.EXACT Therapeutics and its ACT® platform builds on decades of R&D efforts within ultrasound and microbubbles performed by the former world leading diagnostic company; Nycomed Imaging AS (now GE Healthcare). In the late 1990’s and early 2000’s the core technology behind ACT® was developed, with more than $10 M and 40 man-years invested into establishing formulation, manufacturing line, quality control etc. In 2012, three core scientists spun out from GE Healthcare to form Phoenix Solutions, recently renamed to EXACT Therapeutics – with the aim to develop ACT® for therapeutic applications.In 2020 EXACT Therapeutics was listed in the Oslo Stock Exchange Euronext Growth Market under the ticker EXTX-ME.